These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12665805)

  • 21. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

  • 22. Columbia on the fast track. With its merger complete, the new company seeks acquisitions so it can dominate markets.
    Lutz S
    Mod Healthc; 1993 Sep; 23(36):10-1, 14-5. PubMed ID: 10128027
    [No Abstract]   [Full Text] [Related]  

  • 23. Land locked. Some health systems use a buy-and-hold strategy.
    Robeznieks A
    Mod Healthc; 2009 Feb; 39(8):32-3. PubMed ID: 19271634
    [No Abstract]   [Full Text] [Related]  

  • 24. Church & fate. Governance.
    MacPherson P
    Hosp Health Netw; 1996 Mar; 70(6):33-4, 36. PubMed ID: 8593503
    [No Abstract]   [Full Text] [Related]  

  • 25. Is religion a competitive edge?
    Newald J
    Hospitals; 1987 Apr; 61(8):60-4. PubMed ID: 3557399
    [No Abstract]   [Full Text] [Related]  

  • 26. Public and private perspectives on hospital conversions: proposed MUSC-Columbia/HCA "partnership".
    Jones WJ; McIlwain TF
    J Health Hum Serv Adm; 1999; 21(3):325-45. PubMed ID: 10538670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCA's magic act. Going private hinges on unlikely bid to make a mountain of debt vanish.
    Sloane T
    Mod Healthc; 2006 Aug; 36(32):19. PubMed ID: 16958278
    [No Abstract]   [Full Text] [Related]  

  • 28. Systematic attraction. Single hospitals faced with competitive pressures, demand for capital often look to join systems, but money may sour marriage.
    Evans M
    Mod Healthc; 2007 Feb; 37(8):6-7, 12, 1. PubMed ID: 17348342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case study of a failed merger of hospital systems.
    Sidorov J
    Manag Care; 2003 Nov; 12(11):56-60. PubMed ID: 14666587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hospital cost efficiency and system membership.
    Carey K
    Inquiry; 2003; 40(1):25-38. PubMed ID: 12836906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Looking critically at your system's health care businesses.
    Kurtenbach J
    Health Care Strateg Manage; 1999 Feb; 17(2):16-8. PubMed ID: 10345080
    [No Abstract]   [Full Text] [Related]  

  • 32. Biotech IPOs: handle with care.
    Jacobs T
    Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
    [No Abstract]   [Full Text] [Related]  

  • 33. Selecting international markets: lessons from for-profit hospitals.
    Zinn JS; Kashlak RJ; Balotsky ER
    Hosp Health Serv Adm; 1994; 39(1):17-30. PubMed ID: 10132097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Balancing complex choices. Integrating strategic, financial plans will test tomorrow's health networks.
    Cerne F
    Hosp Health Netw; 1993 Jun; 67(12):28-30. PubMed ID: 8508225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the financial characteristics of multi-institutional organizations.
    Coyne JS
    Health Serv Res; 1985 Feb; 19(6 Pt 1):701-15. PubMed ID: 4038697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. For-profits. The right medicine for some markets?
    Lumsdon K; Hagland M
    Hosp Health Netw; 1994 Jun; 68(12):34-6, 38, 40-2. PubMed ID: 8205148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 38. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 39. Hybrid rigor mortis.
    Nat Biotechnol; 2003 Jun; 21(6):585. PubMed ID: 12776128
    [No Abstract]   [Full Text] [Related]  

  • 40. Hybrid vigor.
    Williams K
    Nat Biotechnol; 2003 Aug; 21(8):843. PubMed ID: 12894189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.